Pfizer Inc. (PFE)
After hours:
| Previous Close | 53.99 |
| Open | 53.92 |
| Bid | 53.87 x 1800 |
| Ask | 53.98 x 4000 |
| Day's Range | 53.51 - 54.40 |
| 52 Week Range | 38.48 - 61.71 |
| Volume | |
| Avg. Volume | 27,271,677 |
| Market Cap | 302.484B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | 12.36 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.60 (2.97%) |
| Ex-Dividend Date | May 12, 2022 |
| 1y Target Est | N/A |
- Reuters
U.S. doctors reconsider Pfizer's Paxlovid for lower-risk COVID patients
Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time "is not a crowd-pleaser," Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen.
- Zacks
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
- Zacks
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
